The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus

S Simon, O Joean, T Welte… - European Respiratory …, 2023 - Eur Respiratory Soc
Exacerbations of COPD are associated with worsening of the airflow obstruction,
hospitalisation, reduced quality of life, disease progression and death. At least 70% of …

Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine in the elderly Belgian population

S Marbaix, N Dauby, J Mould-Quevedo - Expert review of vaccines, 2023 - Taylor & Francis
ABSTRACT Background Between 2015 and 2019, when 62% of Belgian adults aged≥ 65
years were vaccinated with standard quadrivalent influenza vaccines, influenza caused an …

Real-world evidence in cost-effectiveness analysis of enhanced influenza vaccines in adults≥ 65 years of age: Literature review and expert opinion

M Postma, D Fisman, N Giglio, S Márquez-Peláez… - Vaccines, 2023 - mdpi.com
Influenza vaccination can benefit most populations, including adults≥ 65 years of age, who
are at greater risk of influenza-related complications. In many countries, enhanced vaccines …

[HTML][HTML] Contributions of cost-effectiveness analyses (CEA) to influenza vaccination policy for older adults in Europe

A Chicoye, P Crepey, S Márquez-Peláez, M Postma… - Vaccine, 2023 - Elsevier
This review describes the importance of economic evaluations and real-world evidence
(RWE) for the assessment of enhanced influenza vaccines for older adults in Europe …

Cost-Effectiveness of Adjuvanted Quadrivalent Influenza Vaccine for Adults over 65 in France

M Paccalin, G Gavazzi, Q Berkovitch, H Leleu… - Vaccines, 2024 - mdpi.com
Background: In France, influenza accounts for an average of over one million consultations
with GPs, 20,000 hospitalizations, and 9000 deaths per year, particularly among the over …

Use of Adjuvanted Quadrivalent Influenza Vaccine in Older-Age Adults: A Systematic Review of Economic Evidence

C O'Neill, GE Crealey - Vaccines, 2024 - mdpi.com
Influenza vaccination is an important public health measure that can reduce disease burden,
especially among older persons (those aged 65 and over) who have weaker immune …